Furthermore, expression of CD36 was shown to be higher in obese patients with NAFLD [36], and reduced lipid accumulation after interfering with CD36 has been reported previously [37,38]. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.